A Method for Stabilizing the Proportion of the Reduced Form of Albumin During Cell-Free and Concentrated Ascites Reinfusion Therapy in Patients with Malignant Ascites

Atsushi Ohashi, Shigeru Nakai, Sachie Yamada, Masao Kato, Midori Hasegawa

Research output: Contribution to journalArticle

Abstract

Cell-free and concentrated ascites reinfusion therapy (CART) is used to treat malignant ascites. However, the qualities of albumin in malignant ascites, such as antioxidative activity, may decrease owing to oxidative stress caused by cancer cells and inflammatory reactions. We investigated the fraction percentages of mercaptalbumin (HMA%, reduced form) and non-mercaptalbumin (HNA%, oxidized form) in malignant ascites from 21 patients who received CART and compared the HMA% in the malignant ascites and human serum albumin (HSA) preparations. HMA% of albumin in malignant ascites (22.5%) was significantly lower than that in HSA preparation (42.2%). To ensure a high HMA%, we added L-cysteine to the paracentesis-treated ascites followed by dialysis 1 h later. As a result, the HMA% of albumin in malignant ascites was increased to 59.1%. Our results suggest that using this method in CART will improve patient's albumin quality.

Original languageEnglish
Pages (from-to)242-247
Number of pages6
JournalTherapeutic Apheresis and Dialysis
Volume23
Issue number3
DOIs
Publication statusPublished - 01-06-2019

Fingerprint

Ascites
Albumins
Therapeutics
Serum Albumin
Paracentesis
Cysteine
Dialysis
Oxidative Stress

All Science Journal Classification (ASJC) codes

  • Hematology
  • Nephrology

Cite this

@article{41492c3fcdb049dc80838b6bc9a27e22,
title = "A Method for Stabilizing the Proportion of the Reduced Form of Albumin During Cell-Free and Concentrated Ascites Reinfusion Therapy in Patients with Malignant Ascites",
abstract = "Cell-free and concentrated ascites reinfusion therapy (CART) is used to treat malignant ascites. However, the qualities of albumin in malignant ascites, such as antioxidative activity, may decrease owing to oxidative stress caused by cancer cells and inflammatory reactions. We investigated the fraction percentages of mercaptalbumin (HMA{\%}, reduced form) and non-mercaptalbumin (HNA{\%}, oxidized form) in malignant ascites from 21 patients who received CART and compared the HMA{\%} in the malignant ascites and human serum albumin (HSA) preparations. HMA{\%} of albumin in malignant ascites (22.5{\%}) was significantly lower than that in HSA preparation (42.2{\%}). To ensure a high HMA{\%}, we added L-cysteine to the paracentesis-treated ascites followed by dialysis 1 h later. As a result, the HMA{\%} of albumin in malignant ascites was increased to 59.1{\%}. Our results suggest that using this method in CART will improve patient's albumin quality.",
author = "Atsushi Ohashi and Shigeru Nakai and Sachie Yamada and Masao Kato and Midori Hasegawa",
year = "2019",
month = "6",
day = "1",
doi = "10.1111/1744-9987.12827",
language = "English",
volume = "23",
pages = "242--247",
journal = "Therapeutic Apheresis and Dialysis",
issn = "1744-9979",
publisher = "Wiley-Blackwell",
number = "3",

}

A Method for Stabilizing the Proportion of the Reduced Form of Albumin During Cell-Free and Concentrated Ascites Reinfusion Therapy in Patients with Malignant Ascites. / Ohashi, Atsushi; Nakai, Shigeru; Yamada, Sachie; Kato, Masao; Hasegawa, Midori.

In: Therapeutic Apheresis and Dialysis, Vol. 23, No. 3, 01.06.2019, p. 242-247.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A Method for Stabilizing the Proportion of the Reduced Form of Albumin During Cell-Free and Concentrated Ascites Reinfusion Therapy in Patients with Malignant Ascites

AU - Ohashi, Atsushi

AU - Nakai, Shigeru

AU - Yamada, Sachie

AU - Kato, Masao

AU - Hasegawa, Midori

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Cell-free and concentrated ascites reinfusion therapy (CART) is used to treat malignant ascites. However, the qualities of albumin in malignant ascites, such as antioxidative activity, may decrease owing to oxidative stress caused by cancer cells and inflammatory reactions. We investigated the fraction percentages of mercaptalbumin (HMA%, reduced form) and non-mercaptalbumin (HNA%, oxidized form) in malignant ascites from 21 patients who received CART and compared the HMA% in the malignant ascites and human serum albumin (HSA) preparations. HMA% of albumin in malignant ascites (22.5%) was significantly lower than that in HSA preparation (42.2%). To ensure a high HMA%, we added L-cysteine to the paracentesis-treated ascites followed by dialysis 1 h later. As a result, the HMA% of albumin in malignant ascites was increased to 59.1%. Our results suggest that using this method in CART will improve patient's albumin quality.

AB - Cell-free and concentrated ascites reinfusion therapy (CART) is used to treat malignant ascites. However, the qualities of albumin in malignant ascites, such as antioxidative activity, may decrease owing to oxidative stress caused by cancer cells and inflammatory reactions. We investigated the fraction percentages of mercaptalbumin (HMA%, reduced form) and non-mercaptalbumin (HNA%, oxidized form) in malignant ascites from 21 patients who received CART and compared the HMA% in the malignant ascites and human serum albumin (HSA) preparations. HMA% of albumin in malignant ascites (22.5%) was significantly lower than that in HSA preparation (42.2%). To ensure a high HMA%, we added L-cysteine to the paracentesis-treated ascites followed by dialysis 1 h later. As a result, the HMA% of albumin in malignant ascites was increased to 59.1%. Our results suggest that using this method in CART will improve patient's albumin quality.

UR - http://www.scopus.com/inward/record.url?scp=85067399853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067399853&partnerID=8YFLogxK

U2 - 10.1111/1744-9987.12827

DO - 10.1111/1744-9987.12827

M3 - Article

VL - 23

SP - 242

EP - 247

JO - Therapeutic Apheresis and Dialysis

JF - Therapeutic Apheresis and Dialysis

SN - 1744-9979

IS - 3

ER -